Thrasyvoulos G. Tzellos

Bodo, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications

A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.

A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.

Journal: Acta dermato-venereologica
Published: April 07, 2026

Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results.

Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 25, 2026

Criteria for Hidradenitis Suppurativa Competence Centers.

Criteria for Hidradenitis Suppurativa Competence Centers.

Journal: Dermatology and therapy
Published: March 20, 2026

Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update.

Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update.

Journal: International journal of dermatology
Published: March 13, 2026

Hidradenitis suppurativa – new treatment options on the way

Hidradenitis suppurativa – new treatment options on the way

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
Published: January 20, 2026

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.

Journal: JAMA dermatology
Published: November 26, 2025

Long-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and MAIC.

Long-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and MAIC.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 02, 2025

Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt Treatment.

Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt Treatment.

Journal: American journal of clinical dermatology
Published: September 26, 2025

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa.

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 24, 2025

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II.

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 09, 2025

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment.

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 02, 2025

Presence of draining tunnels denotes a distinct hidradenitis suppurativa phenotype.

Presence of draining tunnels denotes a distinct hidradenitis suppurativa phenotype.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 06, 2025
Showing 1-12 of 67

Last Updated: 09/26/2026